• January 9-12, 2017 in San Francisco, CA 

In 2016, Onxeo has achieved a number of significant milestones, positioning the Company for success in 2017 and beyond. With a robust pipeline focused on addressing unmet medical needs in the treatment of rare cancers, Onxeo is poised to become the leader in orphan oncology.

Onxeo has a promising therapeutic pipeline with multiple assets in various stages of development, including:

• AsiDNA™ – First-in-class DNA Repair Signal-Interfering Technology with compelling preclinical and clinical data – expected to enter a Phase I clinical trial as a systemic monotherapy in 2017
• Livatag® – Novel, nanoparticle formulation of doxorubicin currently in a Phase III study in hepatocellular carcinoma (primary liver cancer) – preliminary data expected mid-2017
• Beleodaq® (belinostat) – Commercialized as a second-line treatment for Peripheral T-Cell Lymphoma (PTCL) – recently announced promising preclinical results from studies evaluating Beleodaq® in combination with checkpoint inhibitors as a potential treatment option for certain tumor types

For additional information or to schedule a meeting, please contact Lee Roth of The Ruth Group at lroth@theruthgroup.com or 646-536-7012.

161222EN_Onxeo JP Morgan Alert